SKI-606 (Bosutinib) Blocks Prostate Cancer Invasion, Growth, and Metastasis In vitro and In vivo through Regulation of Genes Involved in Cancer Growth and Skeletal Metastasis

In the current study, we have examined the efficacy of a Src/Abl kinase inhibitor SKI-606 (Bosutinib) for its effect on prostate cancer growth and skeletal metastasis. Treatment of highly invasive human prostate cancer cells PC-3 and DU-145 with different doses of SKI-606 decreased Src activation, cell proliferation, migration, and invasion as determined by Matrigel Boyden chamber invasion assay. For in vivo studies, PC-3 cells were inoculated through s.c. or i.t. route into male BALB/c nu/nu or Fox Chase severe combined immunodeficient mice, respectively. Experimental animals treated with SKI-606 developed tumors of a significantly smaller volume and a significant decrease (50%) in experimental skeletal lesion area. A marked increase (32%) in bone volume to tumor volume ratio was also seen by micro–computed tomography analysis of tibias from control and experimental groups of animals. Western blot analysis showed the ability of SKI-606 to significantly decrease the phosphorylation of signaling molecules (AKT, mitogen-activated protein kinase, focal adhesion kinase) and the expression of tumor progression–associated genes uPAR, MMP-2, MMP-9, N-cadherin, fibronectin, BMP-2 (bone morphogenetic protein 2), BMP-6 (bone morphogenetic protein 6), IL-8 (interleukin 8), and TGF-β (transforming growth factor β) in prostate cancer cells. SKI-606 is currently in clinical trials for breast cancer and chronic myelogenous leukemia. Results from these studies provide convincing evidence for evaluating its efficacy in prostate cancer patients. Mol Cancer Ther; 9(5); 1147–57. ©2010 AACR.

[1]  K. Gravdal,et al.  A Switch from E-Cadherin to N-Cadherin Expression Indicates Epithelial to Mesenchymal Transition and Is of Strong and Independent Importance for the Progress of Prostate Cancer , 2007, Clinical Cancer Research.

[2]  G. Castoria,et al.  Src-dependent signalling pathway regulation by sex-steroid hormones: therapeutic implications. , 2007, The international journal of biochemistry & cell biology.

[3]  Larry Norton,et al.  Latent bone metastasis in breast cancer tied to Src-dependent survival signals. , 2009, Cancer cell.

[4]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[5]  D. Boschelli,et al.  SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. , 2003, Cancer research.

[6]  Fei Ye,et al.  7-Alkoxy-4-phenylamino-3-quinolinecar-bonitriles as dual inhibitors of Src and Abl kinases. , 2004, Journal of medicinal chemistry.

[7]  Paul J. Williams,et al.  C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. , 2003, Cancer research.

[8]  Meng Yang,et al.  The Bisphosphonate Olpadronate Inhibits Skeletal Prostate Cancer Progression in a Green Fluorescent Protein Nude Mouse Model , 2006, Clinical Cancer Research.

[9]  F. Lee,et al.  Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. , 2006, The American journal of pathology.

[10]  Zhengxin Wang,et al.  Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. , 2008, Cancer research.

[11]  S. Ashley,et al.  Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells , 2004, Clinical Cancer Research.

[12]  W. Zhong,et al.  CD147, MMP-1, MMP-2 and MMP-9 Protein Expression as Significant Prognostic Factors in Human Prostate Cancer , 2008, Oncology.

[13]  A. Feldman,et al.  Modulation of Tumor-host Interactions, Angiogenesis, and Tumor Growth by Tissue Inhibitor of Metalloproteinase 2 via a Novel Mechanism , 2004, Cancer Research.

[14]  S. Ben‐Sasson,et al.  Lyn Is a Target Gene for Prostate Cancer , 2004, Cancer Research.

[15]  L. Scapozza,et al.  In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. , 2006, Cancer research.

[16]  K. Mangold,et al.  Prostate cancer cells regulate growth and differentiation of bone marrow endothelial cells through TGFβ and its receptor, TGFβRII , 2006 .

[17]  K. Chan,et al.  The prognostic significance of BMP-6 signaling in prostate cancer , 2008, Modern Pathology.

[18]  K. Fizazi,et al.  The role of Src in prostate cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  H. Nielsen,et al.  TIMP-1 Is Significantly Associated with Objective Response and Survival in Metastatic Colorectal Cancer Patients Receiving Combination of Irinotecan, 5-Fluorouracil, and Folinic Acid , 2007, Clinical Cancer Research.

[20]  Yong Li,et al.  Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. , 2006, Human pathology.

[21]  Ya Cao,et al.  Adenovirus‐mediated expression of TIMP‐1 and TIMP‐2 in bone inhibits osteolytic degradation by human prostate cancer , 2008, International journal of cancer.

[22]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[23]  Xìao-chun Xu,et al.  Prognostic significance of MMP‐9 and TIMP‐1 serum and tissue expression in breast cancer , 2008, International journal of cancer.

[24]  E. Schwarz,et al.  Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. , 2006, Bone.

[25]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[26]  C. Logothetis,et al.  Targeting Src signaling in metastatic bone disease , 2009, International journal of cancer.

[27]  H. Varmus,et al.  Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice. , 1997, Genes & development.

[28]  R. Jove,et al.  SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells , 2008, Molecular Cancer Therapeutics.

[29]  L. Otterbein,et al.  N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. , 2006, Journal of medicinal chemistry.

[30]  A. Jimeno,et al.  Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts , 2009, Molecular Cancer Therapeutics.

[31]  S. Rabbani,et al.  A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. , 2007, Cancer research.

[32]  M. Szyf,et al.  DNA Methyltransferase Is a Downstream Effector of Cellular Transformation Triggered by Simian Virus 40 Large T Antigen* , 1999, The Journal of Biological Chemistry.

[33]  Yi Lu,et al.  Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. , 2005, Cancer research.

[34]  H. Kung,et al.  Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530 , 2008, Oncogene.

[35]  S. Yeh,et al.  1α,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases , 2005 .

[36]  Archana Sanjay,et al.  Src Kinase Activity Is Essential for Osteoclast Function* , 2004, Journal of Biological Chemistry.

[37]  D. Boschelli,et al.  Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. , 2001, Journal of medicinal chemistry.

[38]  Fei Ye,et al.  SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. , 2005, Cancer research.

[39]  Shihua Sun,et al.  Changes in Androgen Receptor Nongenotropic Signaling Correlate with Transition of LNCaP Cells to Androgen Independence , 2004, Cancer Research.

[40]  H. Kung,et al.  Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK , 2004, Oncogene.

[41]  J. Cheng,et al.  Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. , 2005, Cancer research.

[42]  A. Borowsky,et al.  Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. , 2009, Cancer research.

[43]  M. Szyf,et al.  Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. , 2006, Cancer research.

[44]  R. Vessella,et al.  Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis , 2009, British Journal of Cancer.